Scarica l'app Stockscreener
36.02
2.38%
-0.88
Dopo l'orario di chiusura:
36.02
Precedente Chiudi:
$36.90
Aprire:
$36.77
Volume 24 ore:
959.88K
Relative Volume:
0.66
Capitalizzazione di mercato:
$2.85B
Reddito:
-
Utile/perdita netta:
$-119.67M
Rapporto P/E:
-13.19
EPS:
-2.73
Flusso di cassa netto:
$-97.30M
1 W Prestazione:
-5.71%
1M Prestazione:
-11.82%
6M Prestazione:
+151.54%
1 anno Prestazione:
+202.69%
Intervallo 1D:
$35.73
$37.90
Intervallo di 1 settimana:
$35.73
$39.15
Portata 52W:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER ROAD, RADNOR
Confronta MLYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
36.02 | 2.92B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Boothbay Fund Management LLC Sells 116,877 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Aug Opening: Is Mineralys Therapeutics Inc stock a contrarian buyPortfolio Performance Report & Daily Technical Stock Forecast Reports - moha.gov.vn
Biotech Shake-Up: New CEO Takes Helm at Jubilant Therapeutics - MyChesCo
Mineralys hypertension drug trial featured in JAMA’s top research of 2025 - Investing.com Canada
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) 'Research of the Year” Roundup - The Manila Times
Mineralys (Nasdaq: MLYS) Launch-HTN Cuts BP 19.0 mmHg, Lands JAMA Research of Year - Stock Titan
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
73,921 Shares in Mineralys Therapeutics, Inc. $MLYS Acquired by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Price-Driven Insight from (MLYS) for Rule-Based Strategy - news.stocktradersdaily.com
Swiss National Bank Invests $838,000 in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
22NW LP Purchases 98,698 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Pale Fire Capital SE - MarketBeat
Aug Big Picture: How Mineralys Therapeutics Inc stock reacts to inflationary pressuresInsider Buying & Low Volatility Stock Suggestions - BỘ NỘI VỤ
Is Mineralys Therapeutics Inc a good long term investmentMarket Timing Techniques & High Return Investment Plans - earlytimes.in
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - sharewise.com
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Quadrature Capital Ltd - MarketBeat
Is Mineralys Therapeutics Inc. stock a buy for dividend growthJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
How Mineralys Therapeutics Inc. stock valuations compare to rivalsQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - Newser
Mineralys Therapeutics Earnings Notes - Trefis
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys - AOL.com
AZ uses a priority review voucher for baxdrostat filing - pharmaphorum
Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Geode Capital Management LLC - MarketBeat
AstraZeneca Moves Ahead of Mineralys With Fast Baxdrostat Review - Citeline News & Insights
Virtus Investment Advisers LLC Sells 7,192 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Prudential Financial Inc. Increases Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga
Will Mineralys Therapeutics Inc. stock rally after Fed decisions - Newser
How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing - Sahm
Ensign Peak Advisors Inc Raises Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
(MLYS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital’s Major New Investment - Yahoo Finance
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Franklin Resources Inc. - MarketBeat
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ProShare Advisors LLC Takes $141,000 Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling - Investing.com
Mineralys Therapeutics Insider Sold Shares Worth $43,350,000, According to a Recent SEC Filing - MarketScreener
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m By Investing.com - Investing.com Australia
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m - Investing.com India
Mineralys Therapeutics, Inc.Common Stock (Nasdaq:MLYS) Stock Quote | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Director’s Major Stock Sale Shakes Up Mineralys Therapeutics! - TipRanks
[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity - Stock Titan
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):